FindTrial
Sign In

Therapeutic effect of the Exenatide in the treatment of polycystic ovary syndrome

Therapeutic effect of the Exenatide in the treatment of polycystic ovary syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16008242
Enrollment
Unknown
Registered
2016-04-07
Start date
2016-04-25
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovary syndrome

Interventions

Exenatide group:Exenatide+metformin
metformin group:metformin

Sponsors

Shengjing Hospital affiliated to China Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Aged greater than 18 years of age, less than 45 years; 2. Diagnosis of polycystic ovarian syndrome (according to the 2003 Rotterdam diagnostic criteria); 3. Willing to sign informed consent and provide information.

Exclusion criteria

Exclusion criteria: 1. A history of pancreatitis or a family history; 2. Other endocrine disorders, such as thyroid disease, Cushing's syndrome, hyperlipidemia, delayed congenital adrenal hyperplasia (CAH) and other similar symptoms of the disease; 3. Any type of malignancy (whether or not cured).

Design outcomes

Primary

MeasureTime frame
BMI;peptide;insulin;waist-hip ratio;LH/FSH;testosteron;estradiol;menstrual cycle;blood lipids concentration;blood sugar concentration;prog;PRL;Blood 17 hydroxy progesterone;Uterine and ovarian ultrasonography;—

Countries

China

Contacts

Public ContactLi Ling

Shengjing Hospital affiliated to China Medical University

liling@sj-hospital.org+86 18940251181

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026